Enphase Energy Inc vs GeneDx Holdings Corp — how do they compare? Enphase Energy Inc trades at $41.09 (market cap $5.81B), while GeneDx Holdings Corp trades at $63.44 (market cap $1.96B). The key difference: Enphase Energy Inc is far larger — about 3× GeneDx Holdings Corp's market cap, and Enphase Energy Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ENPH | WGS | |
|---|---|---|
Market Cap | $5.81B | $1.96B |
Sector | Technology | Technology |
52-Week High | $72.33 | $167.51 |
52-Week Low | $26.12 | $34.51 |
Enterprise Value | $5.46B | $1.96B |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.59, down 7.55% in the past 24 hours, reflecting recent bearish pressure. The stock shows a mixed technical picture with support near $39 and resistance at $44, while fundamentals indicate solid profitability with a 44.23% gross margin and consistent earnings beats in recent quarters. Recent news highlights product expansions in Europe and Australia, alongside positive analyst coverage citing long-term tailwinds despite short-term challenges.
Outlook remains cautiously optimistic with a consensus price target of $42.79, slightly above current levels. Key opportunities include global product rollouts and high margins, but risks involve revenue volatility, competitive pressures, and ongoing legal scrutiny. Investors should weigh strong fundamentals against near-term stock weakness and market sentiment shifts.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Trailing returns across standard periods
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →